Cargando…

Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors

BACKGROUND: The objective of this study was to report on the long‐term effects of pexidartinib on tenosynovial giant cell tumor (TGCT). METHODS: This was a pooled analysis encompassing 3 pexidartinib‐treated TGCT cohorts: 1) a phase 1 extension study (NCT01004861; 1000 mg/d; n = 39), 2) ENLIVEN pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gelderblom, Hans, Wagner, Andrew J., Tap, William D., Palmerini, Emanuela, Wainberg, Zev A., Desai, Jayesh, Healey, John H., van de Sande, Michiel A. J., Bernthal, Nicholas M., Staals, Eric L., Peterfy, Charles G., Frezza, Anna Maria, Hsu, Henry H., Wang, Qiang, Shuster, Dale E., Stacchiotti, Silvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946703/ https://www.ncbi.nlm.nih.gov/pubmed/33197285 http://dx.doi.org/10.1002/cncr.33312

Ejemplares similares

Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial
por: Van De Sande, Michiel, et al.
Publicado: (2021)

Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor
por: Yin, Ophelia, et al.
Publicado: (2021)

Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Pexidartinib Long‐Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors
por: Lewis, James H., et al.
Publicado: (2020)

Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations
por: Vaynrub, Anna, et al.
Publicado: (2022)

Complementary Effects of Surgery and Pexidartinib in the Management of Patients with Complex Diffuse-Tenosynovial Giant Cell Tumor
por: Bernthal, Nicholas M., et al.
Publicado: (2022)

The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study
por: Bernthal, Nicholas M., et al.
Publicado: (2021)

Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory Disease
por: Healey, John H., et al.
Publicado: (2020)

Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies
por: Palmerini, Emanuela, et al.
Publicado: (2023)

Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature
por: Giustini, Nicholas, et al.
Publicado: (2018)

A prospective real‐world study of the diffuse‐type tenosynovial giant cell tumor patient journey: A 2‐year observational analysis
por: Bernthal, Nicholas M., et al.
Publicado: (2022)

Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor
por: Monestime, Shanada, et al.
Publicado: (2020)

Limb Amputation after Multiple Treatments of Tenosynovial Giant Cell Tumour: Series of 4 Dutch Cases
por: Mastboom, Monique J. L., et al.
Publicado: (2017)

Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor
por: Verspoor, F. G. M., et al.
Publicado: (2019)

Patient-reported Symptoms of Tenosynovial Giant Cell Tumors
por: Gelhorn, Heather L., et al.
Publicado: (2016)

Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis
por: Thongchot, Suyanee, et al.
Publicado: (2022)

MRI of diffuse-type tenosynovial giant cell tumour in the knee: a guide for diagnosis and treatment response assessment
por: Spierenburg, Geert, et al.
Publicado: (2023)

Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics
por: Zahir, Hamim, et al.
Publicado: (2022)

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects
por: Zahir, Hamim, et al.
Publicado: (2022)

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
por: Tap, William D., et al.
Publicado: (2022)

Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development
por: Benner, Brooke, et al.
Publicado: (2020)

A novel colony‐stimulating factor 1 (CSF1) translocation involving human endogenous retroviral element in a tenosynovial giant cell tumor
por: Lipplaa, Astrid, et al.
Publicado: (2023)

Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands
por: Mastboom, Monique J L, et al.
Publicado: (2017)

Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors
por: van IJzendoorn, David G.P., et al.
Publicado: (2022)

The Patient Perspective on the Impact of Tenosynovial Giant Cell Tumors on Daily Living: Crowdsourcing Study on Physical Function and Quality of Life
por: Mastboom, Monique Josephine, et al.
Publicado: (2018)

Pexidartinib: First Approval
por: Lamb, Yvette N.
Publicado: (2019)

Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
por: Mastboom, Monique J L, et al.
Publicado: (2018)

Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry
por: Lopez-Bastida, J., et al.
Publicado: (2021)

Chondroid Tenosynovial Giant Cell Tumor of Temporomandibular Joint
por: Shetty, Sujeeth Kumar, et al.
Publicado: (2018)

Cryosurgery as Additional Treatment in Tenosynovial Giant Cell Tumors
por: Verspoor, F. G. M., et al.
Publicado: (2016)

The measurement of physical functioning among patients with Tenosynovial Giant Cell Tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS)
por: Gelhorn, Heather L., et al.
Publicado: (2019)

Localized tenosynovial giant cell tumor in children
por: Du, Xifeng, et al.
Publicado: (2023)

One-Stage Synovectomies Result in Improved Short-Term Outcomes Compared to Two-Stage Synovectomies of Diffuse-Type Tenosynovial Giant Cell Tumor (D-TGCT) of the Knee: A Multicenter, Retrospective, Cohort Study
por: Spierenburg, Geert, et al.
Publicado: (2023)

Correction to: Pexidartinib: First Approval
por: Lamb, Yvette N.
Publicado: (2020)

Tenosynovial Giant Cell Tumor Arising on the Scapular Region
por: Fukuda, Asako, et al.
Publicado: (2013)

Diffuse Type Tenosynovial Giant Cell Tumor of the Ankle
por: Zhao, Jing-Jing, et al.
Publicado: (2016)

Intramuscular Tenosynovial Giant Cell Tumor, Diffuse-Type
por: Lee, Yoo Jin, et al.
Publicado: (2016)

Tenosynovial giant cell tumor of the distal tibiofibular joint
por: Zarate, Stephanie D., et al.
Publicado: (2021)

Chondroid tenosynovial giant cell tumour of the temporomandibular joint
por: Kanbour, Abdullah, et al.
Publicado: (2021)

Tenosynovial giant cell tumor of the posterior pharyngeal space
por: Poutoglidis, Alexandros, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_360bjmpgam2vijftedtqjdo2kb